STIVARGA® (regorafenib) is approved for use across multiple indications:
mCRC, GIST, and HCC1

Blue graphic of a large intestine

See the potential
in patients
previously treated
for metastatic
colorectal cancer (mCRC)

STIVARGA in mCRC
Green graphic of large and small intestines.

Explore the 3rd-line
treatment of
gastrointestinal
stromal tumor (GIST)

STIVARGA in GIST
Blue graphic of a liver.

Think one step ahead
for your hepatocellular
carcinoma (HCC)
patients previously treated with sorafenib

STIVARGA in HCC

Watch videos from patients and peers to learn more.